Interstitial Cystitis Market Size, Share, Trends, Market forecast, Epidemiology and Leading Companies

1. Interstitial Cystitis Market Size, Share, Trends, Market forecast, Interstitial Cystitis Market Size, Share, Trends, Market forecast, Epidemiology and Leading Companies Epidemiology and Leading Companies DelveInsight has launched a report on “Interstitial Cystitis – Market Insights, Epidemiology, and Market Forecast-2030” DelveInsight’s “Interstitial Cystitis – Market Insights, Epidemiology, and Market Forecast- 2030“ report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the Facts: According to DelveInsight, the total prevalent population of Interstitial Cystitis in the Seven Major Markets was approximately 8,517,779 in 2017. In the epidemiology model, the analysts reported a higher prevalence of Interstitial Cystitis the United States with around 5,000,101 prevalent cases in 2017. Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with 844,367 cases. Spain had the lowest prevalent population of 4,95,983 in 2017.

2. Key facts of the report: Interstitial Cystitis market report covers a descriptive overview and comprehensive insight of the Interstitial Cystitis epidemiology and Interstitial Cystitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) Interstitial Cystitis market report provides insights on the current and emerging therapies. Interstitial Cystitis market report offers a global historical and forecasted market covering drug outreach in 7MM. Interstitial Cystitis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market. Request for Sample Pages: https://www.delveinsight.com/sample-request/interstitial-cystitis- market “As per DelveInsight’s analysis, the estimates suggest higher prevalence of the disease among the females throughout the 7MM” According to the Urology Care Foundation, Interstitial cystitis/bladder pain syndrome (BPS) is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area. Along with this pain occurs in the lower urinary tract, which last for more than 6 weeks, without having an infection or other clear causes. It is a chronic, or long-lasting condition that causes painful urinary symptoms. According to Interstitial Cystitis Association, currently here are two recognized subtypes of Interstitial cystitis: Non ulcerative and Ulcerative. The exact cause of the disease is not known, but there are certain theories, such as a defect in the bladder tissue, which may allow irritating substances in the urine to penetrate the bladder, a specific type of inflammatory cell, called a mast cell. This cell releases histamine and other chemicals that lead to IC/BPS symptoms, changes in the nerves that carry bladder sensations, so pain is caused by events that are generally not painful, the body’s immune system attacks the bladder which is similar to other autoimmune conditions. The symptoms include pain in pelvis or between the vagina and anus in women, and between the scrotum and anus in men (perineum), along with chronic pelvic pain, a persistent, urgent need to urinate, frequent urination—often of small amounts—throughout the day and night (up to 60 times a day), pain or discomfort while the bladder fills, and relief after urinating. Request for Sample Pages: https://www.delveinsight.com/sample-request/interstitial-cystitis- market Some of the key companies working on Interstitial Cystitis are: Lipella Pharmaceuticals Purdue Pharma/Alivio Therapeutics Seikagaku Corporation Kyorin Holdings And Many Others.

3. The launch of the emerging therapies is expected to significantly impact the Interstitial Cystitis treatment scenario in the upcoming years:- Drugs Covered: LP-08 ALV-107 SI-722 KRP-116D And Many Others Request for Sample Pages: https://www.delveinsight.com/sample-request/interstitial-cystitis- market Table of Contents: Key Insights Executive Summary of Interstitial Cystitis Interstitial Cystitis: Market Overview at a Glance 3.1. Total Market Share (%) Distribution of Interstitial Cystitis in 2017 3.2. Total Market Share (%) Distribution of Interstitial Cystitis in 2030 Interstitial Cystitis (IC): Disease Background and Overview 4.1. Introduction 4.2. Causes 4.3. Risk Factors 4.4. Signs and Symptoms 4.5. Pathophysiology 4.6. Biomarkers for patients with interstitial cystitis 4.7. Diagnosis 4.7.1. Consensus panel recommendations for the evaluation and diagnosis of patients with suspected IC/PBS 4.7.2. American Urology Association diagnosis guideline 4.7.3. Society of Interstitial Cystitis of Japan (SICJ) diagnosis guideline Epidemiology and Patient Population 5.1. Population and Forecast Parameters 5.2. Key Findings 5.3. 7MM Total Prevalent Patient Population of Interstitial Cystitis

4. 5.4. 7MM Total Diagnosed Prevalent Patient Population of Interstitial Cystitis Country Wise-Epidemiology of Interstitial Cystitis 6.1. United States 6.1.1. Assumptions and Rationale 6.1.2. Total Prevalent Population of Interstitial Cystitis in the United States 6.1.3. Sex-Specific Prevalent Population of Interstitial Cystitis in the United States 6.1.4. Total Diagnosed Prevalence of Interstitial Cystitis in the United States 6.1.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States 6.2. EU5 Countries 6.2.1. Assumptions and Rationale 6.2.2. Germany 6.2.2.1. Total Prevalent Population of Interstitial Cystitis in Germany 6.2.2.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Germany 6.2.2.3. Total Diagnosed Prevalence of Interstitial Cystitis in Germany 6.2.2.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany 6.2.3. France 6.2.3.1. Total Prevalent Population of Interstitial Cystitis in France 6.2.3.2. Sex-Specific Prevalent Population of Interstitial Cystitis in France 6.2.3.3. Total Diagnosed Prevalence of Interstitial Cystitis in France 6.2.3.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France 6.2.4. Italy 6.2.4.1. Total Prevalent Population of Interstitial Cystitis in Italy 6.2.4.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Italy 6.2.4.3. Total Diagnosed Prevalence of Interstitial Cystitis in Italy 6.2.4.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy 6.2.5. Spain 6.2.5.1. Total Prevalent Population of Interstitial Cystitis in Spain 6.2.5.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Spain 6.2.5.3. Total Diagnosed Prevalence of Interstitial Cystitis in Spain 6.2.5.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain 6.2.6. United Kingdom

5. 6.2.6.1. Total Prevalent Population of Interstitial Cystitis in the United Kingdom 6.2.6.2. Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom 6.2.6.3. Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom 6.2.6.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom 6.3. Japan 6.3.1. Assumptions and Rationale 6.3.2. Total Prevalent Population of Interstitial Cystitis in Japan 6.3.3. Sex-Specific Prevalent Population of Interstitial Cystitis in Japan 6.3.4. Total Diagnosed Prevalence of Interstitial Cystitis in Japan 6.3.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan Treatment Algorithm, Current Treatment, and Medical Practices 7.1. Treatment 7.2. Treatment Algorithm 7.2.1. United States 7.2.2. Japan 7.2.3. Europe Unmet Needs Marketed Drugs 9.1. Elmiron: Janssen Pharmaceutical 9.1.1. Drug Description 9.1.2. Mechanism of action 9.1.3. Regulatory Milestones 9.1.4. Advantages & Disadvantages 9.1.5. Safety and Efficacy 9.1.6. Product Profile Instillations 10.1. RIMSO-50: Mylan Pharmaceutical 10.1.1. Drug Description 10.1.2. Mechanism of Action 10.1.3. Regulatory Milestones

6. 10.1.4. Advantages & Disadvantages 10.1.5. Safety and Efficacy 10.1.6. Product Profile 10.2. Cystistat: Bioniche Life Sciences Inc 10.2.1. Drug Description 10.2.2. Mechanism of Action 10.2.3. Regulatory Milestones 10.2.4. Advantages & Disadvantages 10.2.5. Safety and Efficacy 10.2.6. Product Profile 10.3. Gepan instill: Pohl-Boskamp GmbH 10.3.1. Drug Description 10.3.2. Mechanism of Action 10.3.3. Advantages & Disadvantages 10.3.4. Safety and Efficacy 10.3.5. Product Profile 10.4. Uracyst: Stellar Pharmaceuticals 10.4.1. Drug Description 10.4.2. Regulatory Milestones 10.4.3. Advantages & Disadvantages 10.4.4. Safety and Efficacy 10.4.5. Product Profile 10.4.6. Drug Description 10.4.7. Advantages & Disadvantages 10.4.8. Safety and Efficacy 10.4.9. Product Profile 10.5. iAluRil: Aspire Pharma 10.5.1. Drug Description 10.5.2. Mechanism of Action 10.5.3. Advantages & Disadvantages 10.5.4. Safety and Efficacy

7. 10.5.5. Product Profile List to be continued in the report… Emerging Therapies 11.1. Key Cross Competition 11.2. KRP-116D: Kyorin Holdings 11.2.1. Product Description 11.2.2. Other Developmental Activities 11.2.3. Clinical Development 11.2.4. Safety and Efficacy 11.2.5. Advantages and Disadvantages 11.2.6. Product Profile 11.3. SI-722: Seikagaku Corporation 11.3.1. Product Description 11.3.2. Clinical Development 11.3.3. Product Profile 11.4. LP-08: Lipella Pharmaceuticals 11.4.1. Product Description 11.4.2. Other Developmental Activities 11.4.3. Clinical Development 11.4.4. Safety and Efficacy 11.4.5. Product Profile List to be continued in the report… Interstitial Cystitis: 7 Major Market Analysis 12.1. Key Findings 12.2. Market Size of Interstitial Cystitis in 7MM The United States Market Outlook 13.1. United States Market Size 13.1.1. Total Market size of Interstitial Cystitis in the United States 13.1.2. Market Size by Current Therapies in the United States 13.1.3. Market Size by Emerging Therapies in the United States EU-5 Countries: Market Outlook

8. 14.1. Germany 14.1.1. Total Market size of Interstitial Cystitis in Germany 14.1.2. Market Size by Current Therapies in Germany 14.1.3. Market Size by Emerging Therapies in Germany 14.2. France 14.2.1. Total Market size of Interstitial Cystitis in France 14.2.2. Market Size by Current Therapies in France 14.2.3. Market Size by Emerging Therapies in France 14.3. Italy 14.3.1. Total Market size of Interstitial Cystitis in Italy 14.3.2. Market Size by Current Therapies in Italy 14.3.3. Market Size by Emerging Therapies in Italy 14.4. Spain 14.4.1. Total Market Size of Interstitial Cystitis in Spain 14.4.2. Market Size by Current Therapies in Spain 14.4.3. Market Size by Emerging Therapies in Spain 14.5. United Kingdom 14.5.1. Total Market size of Interstitial Cystitis in the United Kingdom 14.5.2. Market Size by Current Therapies in the United Kingdom 14.5.3. Market Size by Emerging Therapies in the United Kingdom Japan: Market Outlook 15.1. Total Market size of Interstitial Cystitis in Japan 15.2. Market Size by Current Therapies in Japan 15.3. Market Size by Emerging Therapies in Japan Access and Reimbursement Market Drivers Market Barriers SWOT Analysis Appendix 20.1. Report Methodology DelveInsight Capabilities

9. Disclaimer About DelveInsight Related Reports: Interstitial Cystitis – Pipeline Insights, 2020 The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages. Interstitial Cystitis – Epidemiology Forecast to 2030 The Interstitial Cystitis epidemiology covered in the report provides historical as well as forecasted Interstitial Cystitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.